Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BackgroundDiabetic nephropathy (DN) is currently the most common cause of end-stage renal disease (ESRD). Although nowadays much is known about its classification, pathogenesis, clinical manifestations and evolution, to date we are not yet able to stop the natural progression of nephropathy in diabetic patients.MethodsTreatment options are: lifestyle change with close blood pressure monitoring and tight glycemic control. The most common therapies adopted for this condition are Angiotensing Converting Enzyme-inhibitors (ACEi). However these drugs are able to block the progression of renal damage only in a small proportion of patients. In the remaining, DN progresses and may evolve into ESRD.ConclusionThe purpose of this review is to summarize the "state of art" of current novel therapeutic strategies to stem this debilitating kidney disease.

Original publication

DOI

10.2174/138920021705160324165553

Type

Journal article

Journal

Current drug metabolism

Publication Date

01/2016

Volume

17

Pages

497 - 502

Keywords

Humans, Diabetic Nephropathies, Hypoglycemic Agents